AN OPEN-LABEL, SINGLE-ARM 4-YEAR STUDY TO EVALUATE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB TREATMENT IN PATIENTS WITH PROGRESSIVE MULTIPLE SCLEROSIS
Phase of Trial: Phase III
Latest Information Update: 21 Feb 2019
At a glance
- Drugs Ocrelizumab (Primary)
- Indications Multiple sclerosis
- Focus Registrational; Therapeutic Use
- Acronyms CONSONANCE
- Sponsors Roche
- 10 Jan 2019 Planned End Date changed from 31 Jan 2024 to 18 Sep 2025.
- 08 Jun 2018 Planned End Date changed from 1 Oct 2024 to 31 Jan 2024.
- 04 May 2018 New trial record